SEC Comment Letter 0000000000-23-005176 to Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: May 15, 2023 · CIK: 0001029125 · Accession: 0000000000-23-005176
AI Filing Summary & Sentiment
File numbers found in text: 333-271729
Letter
United States securities and exchange commission logo May 15, 2023 Jennifer K. Simpson, Ph.D., MSN, CRNP Chief Executive Officer Panbela Therapeutics, Inc. 712 Vista Blvd, Suite 305 Waconia, Minnesota 55387 Re:Panbela Therapeutics, Inc. Registration Statement on Form S-1 Filed May 8, 2023 File No. 333-271729 Dear Jennifer K. Simpson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua L. Colburn, Esq.
Show Raw Text
United States securities and exchange commission logo
May 15, 2023
Jennifer K. Simpson, Ph.D., MSN, CRNP
Chief Executive Officer
Panbela Therapeutics, Inc.
712 Vista Blvd, Suite 305
Waconia, Minnesota 55387
Re:Panbela Therapeutics, Inc.
Registration Statement on Form S-1
Filed May 8, 2023
File No. 333-271729
Dear Jennifer K. Simpson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua L. Colburn, Esq.